# OnCo record paper-checkmate-648-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-648-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-648-nejm-2022" ;
  schema:name "CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma"@en ;
  schema:description "Adding nivolumab to chemotherapy, or combining nivolumab with ipilimumab without chemotherapy, lengthened survival compared with chemotherapy alone in advanced oesophageal squamous cell carcinoma, with the largest gains in PD-L1-positive tumours."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-648-nejm-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2111380>, <https://pubmed.ncbi.nlm.nih.gov/35108470/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2111380> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Doki Y, Ajani JA, Kato K, et al." ;
  onco:cancers <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-648/> ;
  onco:journals <https://onco.cc/journals/nejm/> .